Evidence map›Paper›PMID 37680716›Full record

ArticleFrontiers in pharmacology2023

Bioanalytical method validation and application to a phase 1, double-blind, randomized pharmacokinetic trial of a standardized

Kirsten M Wright, Melissa Bollen, Jason David, Bridgette Mepham, Armando Alcázar Magaña, Christine McClure, Claudia S Maier, Joseph F Quinn, Amala Soumyanath

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Efficacy and safety ofFrontiers in pharmacology · 2025
    Trial
  2. Review
  3. Withanolides Are Detected in Human Urine Following Oral Administration of aInternational journal of molecular sciences · 2026
    Article
  4. Molecules (Basel, Switzerland) · 2026
    Review
  5. Review
  6. Clustering of chemical profiles ofIndustrial crops and products · 2025
    Article
  7. Review
  8. Can Asiatic Acid fromCancers · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kirsten M WrightDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Melissa BollenDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Jason DavidDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Bridgette MephamDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Armando Alcázar MagañaDepartment of Chemistry, Oregon State University, Corvallis, OR, United States.
Christine McClureDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Claudia S MaierBENFRA Botanical Dietary Supplements Research Center, Oregon Health & Science University, Portland, OR, United States.
Joseph F QuinnDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Amala SoumyanathDepartment of Neurology, Oregon Health & Science University, Portland, OR, United States.
Oregon Health & Science University · USOregon State University · US

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Research Education ComponentP30AG066518 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zachary Beattie · 2020 to 2026
$28.6M
Outreach, Recruitment and Education CoreP30AG008017 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KAYE, JEFFREY A · 1990 to 2019
$27.7M
CAM Research Training in Neuroscience &StressT32AT002688 · NCCIH · OREGON HEALTH & SCIENCE UNIVERSITY · PI OKEN, BARRY S, SOUMYANATH, AMALA · 2005 to 2025
$7.2M
Mechanisms underlying the cognitive effects of Centella asiatica water extract and constituent compounds in the 5xFAD mouse model of Alzheimer's DiseaseU19AT010829 · NCCIH · OREGON HEALTH & SCIENCE UNIVERSITY · PI SOUMYANATH, AMALA · 2020 to 2024
$6.1M
Biological signatures of the cognitive effects of Centella asiaticaR61AT009628 · NCCIH · OREGON HEALTH & SCIENCE UNIVERSITY · PI QUINN, JOSEPH F, SOUMYANATH, AMALA · 2017 to 2019
$522k
Triple Quadrupole/Linear Ion Trap LC-MS/MS for LPIS10RR027878 · NCRR · OREGON STATE UNIVERSITY · PI STEVENS, JAN FREDERIK · 2010 to 2010
$484k
NCATS NIH HHS UL1 TR002369NCCIH NIH HHS R61 AT009628NCCIH NIH HHS T32 AT002688NCCIH NIH HHS U19 AT010829NCRR NIH HHS S10 RR027878NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG066518
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer’s diseasecaffeoylquinic acidCentella asiaticapharmacodynamicspharmacokineticstriterpenevalidation

Identifiers

PMID37680716
PMCPMC10481538
OpenAlexW4386091311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.